Condition
Malignant Mesothelioma
Estimated Enrollment: 60
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Primary Purpose: Treatment
Study ID Numbers: CDR0000564058|COL-ALIMESO|INCA-RECF0441|COL-2006-04
Study First Received: October 5, 2007
Last Updated: May 14, 2011
Estimated Primary Completion Date: May 2011
Primary Outcome Measures:
Individual dosage-adapted protocol|Relationship between pharmacokinetic and pharmacodynamic parameters|Pharmacokinetics|Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD)
Sponsors and Collaborators:
Centre Oscar Lambret|National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT00541073
